Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile. (Q38752663)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Manfred Wuhrer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Gestur Vidarsson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

12

Taco W Kuijpers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

5

Sietse Q Nagelkerke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

10

Theo Rispens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Carolien A M Koeleman

7

object named as

Carolien A M Koeleman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

9

Timo K van den Berg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Christine W Bruggeman

1

object named as

Christine W Bruggeman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

3

Arthur E H Bentlage

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

4

Louise W Treffers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

Suzanne N Lissenberg-Thunnissen

21 March 2020

6

object named as

Suzanne Lissenberg-Thunnissen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

31 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

published in

Journal of Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

204-211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

IgG subclasses and allotypes: from structure to effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Production of therapeutic antibodies with controlled fucosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Glycosylation as a strategy to improve antibody-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Anti-inflammatory actions of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

International consensus report on the investigation and management of primary immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Kawasaki disease: A brief history.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Intravenous immunoglobulins--understanding properties and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Production of recombinant Ig molecules from antigen-selected single B cells and restricted usage of Ig-gene segments by anti-D antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virus-specific immune responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

Antibody therapy for Adult T-cell leukemia-lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4049%2FJIMMUNOL.1700116

21 January 2018

Identifiers

DOI

10.4049/JIMMUNOL.1700116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28566370%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference